Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
A phase II clinical trial with glutamic acid decarboxylase (GAD) 65 formulated with aluminium hydroxide (GAD-alum) has shown efficacy in preserving residual insulin secretion in children and adolescents with recent-onset type 1 diabetes (T1D). We have performed a 4-year follow-up study of 59 of the...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Public Library of Science (PLoS)
2011
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/7beb2246337149e8b59df7e8f7bc3c5c |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|